BCDA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.170

-32%

-0.230

-61.02%

-0.230

-42.5%

Estimates Revision

The market is revising No Change the revenue expectations for BioCardia, Inc. (BCDA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.08%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.35%

In Past 3 Month

Stock Price

Go Up

+1.08%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

No data

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA.O) is -1.48, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess BioCardia Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.99

Current PE

-1.48

Overvalued PE

-0.50

Undervalued PE

-5.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.25

Current EV/EBITDA

-0.93

Overvalued EV/EBITDA

-0.14

Undervalued EV/EBITDA

-2.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

117.03

Current PS

0.00

Overvalued PS

307.27

Undervalued PS

-73.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 17714.87% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 17714.87% over the last month.

Sold

Bought

BCDA News & Events

Events Timeline

No data

News

9.0

2025-12-16Newsfilter

BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy

5.0

2025-12-03Newsfilter

BioCardia Elects Marvin Slosman to Board of Directors

5.0

2025-11-24Yahoo Finance

BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality

People Also Watch

Frequently Asked Questions

What is BioCardia Inc (BCDA) stock price today?

The current price of BCDA is 1.405 USD — it has increased 6.44 % in the last trading day.

What is BioCardia Inc (BCDA)'s business?

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

What is the price predicton of BCDA Stock?

What is BioCardia Inc (BCDA)'s revenue for the last quarter?

BioCardia Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is BioCardia Inc (BCDA)'s earnings per share (EPS) for the last quarter?

BioCardia Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.66 % YoY.

What changes have occurred in the market's expectations for BioCardia Inc (BCDA)'s fundamentals?

How many employees does BioCardia Inc (BCDA). have?

BioCardia Inc (BCDA) has 17 emplpoyees as of January 10 2026.

What is BioCardia Inc (BCDA) market cap?

Today BCDA has the market capitalization of 14.91M USD.